Drug Profile

Gamma delta T cell therapy - Cytomed Therapeutics

Alternative Names: CTM-GDT; gdTc - Cytomed Therapeutics

Latest Information Update: 31 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CytoMed Therapeutics
Developer CytoMed Therapeutics; University of Texas M. D. Anderson Cancer Center
Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

02 Oct 2025 Preclinical trials in Acute myeloid leukaemia in Singapore (Parenteral)
02 Oct 2025 Preclinical trials in Solid tumours in Singapore (Parenteral) (Cytomed Therapeutics pipeline, October 2025)
02 Oct 2025 CytoMed Therapeutics plans clinical trials for acute myeloid leukemia and solid tumours in Southeast Asia

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com